Biologics Market Share, Size by Source (Microbial) Product (Monoclonal Antibodies) by Disease Category (Oncology), by Biologics Manufacturing (Outsourced) and Region (Asia Pacific, Europe, North America, Middle East, and Africa, Latin America), and forecast period-2022 – 2030 (Updated Version Available)

Report ID - MRC_697 | Pages - 157 | Category - Healthcare and Pharma

Biologics Market Insights

Biologics Market is projected to be worth USD 432.45 Billion by 2030, registering a CAGR of 3.2% during the forecast period (2022-2030), the market was valued at USD 325.70 Billion in 2021. microbial source is expected to dominate the growth of the market due to a significant number of medications produced utilising these items. Monoclonal antibodies (MABs) led the market with the highest revenue share owing to increasing use of this class of medications in several therapeutic fields. The North American biologics market held the greatest share of 72.5% in 2019 due to the presence of prominent corporations, favourable reimbursement regulations, and significant R&D spending.

Biologics Market Dynamics:

Drugs identified as biologics are manufactured as genetically engineered proteins generated from genes of human. Biologics can be composed of proteins, carbohydrates, complicated mixtures or nucleic acids, of these elements, along with possibly live things like tissues and cells. The majority of biologics are complicated mixtures that are difficult to recognize or describe, and are heat sensitive, and vulnerable to microbial contamination. The biologic products originated from a range of uncultivated sources, such as animals, people, and microorganisms.

How much is the Biologics Market worth ?

img

Get Free Sample PDF

Driver:

Growing financial investments from major market participants, an increase in the prevalence of chronic diseases, the loss of patent exclusivity for the top biologic medications, and rising demand and acceptance for novel therapies are the main market drivers. Further, rising investments by key manufactures such as Biocon Ltd in biosimilar business is expected to fuel the market expansion.

Restraint:

The market growth was constrained by strict regulatory requirements, high capital expenditures, and loss of patent exclusivity in the biologics business. Further, the reduced availability and affordability of biologics in middle- and low-income nations is expected to hamper the growth of the market during the forecast period.

 COVID-19 Analysis of Biologics Market:

The biologics market has been severely impacted since the COVID-19 epidemic in many different parts of the world. Shipments were impacted during the initial lockdown due to a labor shortage and the closure of a manufacturing facility. The pandemic’s initial effects on China were tremendous. However, the nation’s circumstances have stabilized, and all product and service production rates have increased. As a result, it is determined that COVID-19’s overall impact on the biologics market is moderate.

Biologics Report Coverage: 

Report Attributes Report Details
Study Timeline 2016-2030
Market Size in 2030 (USD Billion) 432.45
CAGR (2022-2030) 3.2%
By Source Microbial, Mammalian, Others
By Product ·         Monoclonal Antibodies

o   MABs by application

§  Diagnostic

·         Biochemical Analysis

·         Diagnostic Imaging

§  Therapeutic

·         Direct MAB Agents

·         Targeting MAB Agents

§  Protein Purification

§  Others

o   MABs by type

§  Murine

§  Chimeric

§  Humanized

§  Human

§  Others

·         Vaccines

·         Recombinant Proteins

·         Antisense, RNAi, & Molecular Therapy

·         Other

By Disease Category ·         Oncology

o   By Product

§  MABs

§  Vaccines

§  Recombinant Proteins

§  Antisense, RNAi, & Molecular Therapy

§  Others

·         Infectious Diseases

o   By Product

§  Vaccines

§  MABs

§  Antisense, RNAi, & Molecular Therapy

§  Recombinant Proteins

§  Others

·         Immunological Disorders

·         Cardiovascular Disorders

·         Hematological Disorders

·         Others

By Biologics Manufacturing ·         Outsourced

·         In-house

By geography North America– (U.S., Canada, Mexico

Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe)

Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific)

Latin America- (Brazil, Argentina, Chile, Rest of Latin America)

Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA)

Key Players Samsung BioLogics; Amgen; Novo Nordisk A/S; AbbVie Inc.; Sanofi; Johnson & Johnson Services, Inc; Pfizer Inc.; Merck & Co., Inc.; GSK group of companies; Celltrion; Precision Biologics, Inc.; Merck KGaA; Eli Lilly and Company; Novartis AG; Bayer AG; F. Hoffmann-La Roche Ltd; AstraZeneca

Biologics Market Segment Analysis:

By Source

These biopharmaceuticals are divided into microbial, mammalian, and others.  Due to a significant number of medications produced utilising these items, microbial source is expected to dominate the growth of the market. Yeast and Escherichia coli are frequently covered by microbial expression systems. Recombinant insulin, granulocyte-macrophage colony-stimulating factor, platelet-derived growth factor, and recombinant interferon are examples of products created using these expression systems. The companies using microbial systems are Johnson & Johnson, Novartis, and Genentech. Hence, microbial source is expected to support the growth of the biologics market.

By Product

Monoclonal antibodies (MABs) led the market with the highest revenue share owing to increasing use of this class of medications in several therapeutic fields. Healthy cells can be targeted with MABs without suffering any negative effects. Additionally, these medications are particularly helpful in the management of cancer and the treatment of autoimmune illnesses, such as rheumatoid arthritis.

Biologics Market Size

By Disease Category

The increased incidence of cancer and the existence of numerous R&D programmes led to oncology segment for high share in the 2021. These initiatives involve antisense medicines and gene treatments for the elimination of cancer. Additionally, oncology segment is expected to maintain its dominance during the forecast period. Rising product adoption to lessen the string of unfavourable side effects related to the use of cancer chemotherapy is one of the factors driving the expected rise.

By Biologics Manufacturing

Biologics manufacturing segment includes outsourced and in house. In-house segment is expected to gain significant market. As manufacturers are choosing to produce rather than outsourcing the services form contract research organization. This has instigated a higher percentage of biologics to be manufactured internally. Businesses are investing in their own bioprocessing resources. This factor is expected to drive the growth of the in-house segment in the biologics market.

biologics market by biologics

By Region

The North American biologics market held the greatest share of 72.5% in 2019 due to the presence of prominent corporations, favourable reimbursement regulations, and significant R&D spending. Approximately 38% of all pharma expenditures in the US are for biologics. Throughout the projection period, the FDA in the United States is expected to approve additional biologic medications, such as the 21 BLAs they approved in 2021. Due to increased R&D expenditures for biologic development and the presence of numerous biologics with FDA approval in the US, the US market for biologics accounted for a sizeable portion in 2021.

The market for biologics in Europe is dominated by Germany. The dominance of this market in Europe is attributed to the presence of a sophisticated manufacturing industry, favourable reimbursement, the availability of numerous approved medications, and the target patient demographic.

Biologics Market Competitive Landscape:

The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Further, the surge in Research and Development (R&D), product innovation, various business strategies, and product launches have accelerated the growth of the Biologics market. Key players in the market include-

  • Samsung BioLogics
  • Amgen
  • Novo Nordisk A/S
  • AbbVie Inc.
  • Sanofi
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GSK group of companies
  • Celltrion
  • Precision Biologics, Inc.
  • Merck KGaA
  • Eli Lilly and Company
  • Novartis AG
  • Bayer AG
  • Hoffmann-La Roche Ltd
  • AstraZeneca

Recent Development:

  • The Janssen Pharmaceutical Companies of Johnson & Johnson received FDA approval for CARVYKTI in 2022 to treat adults with RRMM following four or more prior lines of therapy, such as immunomodulatory agent, proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Table of Content

  1. Introduction
    • Market Introduction
    • Market Research Methodology
      • Research Process
      • Primary Research
      • Secondary Research
      • Data Collection Technique
      • Data Sources
    • Market Estimation Methodology
      • Limitations of the Study
    • Product Picture of Microarray Analysis
    • Global Biologics Market: Classification
    • Geographic Scope
    • Years Considered for the Study
    • Research Methodology in brief
    • Parent Market Overview
    • Overall Biologics Market Regional Demand
    • Research Programs/Design
    • Market Breakdown and Data Triangulation Approach
    • Data Source
    • Secondary Sources
    • Primary Sources
    • Primary Interviews
    • Average primary breakdown ratio
  2. Market Dynamics
    • Drivers
      • Drivers
    • Restraints
      • Restraints
    • Opportunity
      • Impact forces on market dynamics
      • Impact forces during the forecast years
    • Industry Value Chain
      • Upstream analysis
      • Downstream analysis
      • Disease Category
      • Direct Channel
      • Indirect Channel
    • Potential Customers
    • Manufacturing/Operational Cost Analysis
    • Pricing Analysis by Region
    • Key Product Landscape
    • Regulatory Analysis
    • Porter’s Analysis
      • Supplier Power
      • Buyer Power
      • Substitution Threat
      • Threat from New Entry
      • Competitive Rivalry
    • PESTEL Analysis
    • Political Factors
    • Economic Factor
    • Social Factors
    • Technological Factor
    • Environmental Factors
    • Legal Factor
    • Covid-19 impact on Global Economy
    • Covid-19 impact on Microarray Analysis demand
    • Post-Covid Impact on Biologics Market Demand
    • Impact Analysis of Russia-Ukraine Conflict
  3. Global Biologics Market Segmentation, Revenue (USD Billion), (2022-2030)
    • By Source
      • Microbial
      • Mammalian
      • Others
    • By Product
      • Monoclonal Antibodies
        • MABs by application
          • Diagnostic
            • Biochemical Analysis
            • Diagnostic Imaging
          • Therapeutic
            • Direct MAB Agents
            • Targeting MAB Agents
          • Protein Purification
          • Others
        • MABs by type
          • Murine
          • Chimeric
          • Humanized
          • Human
          • Others
        • Vaccines
        • Recombinant Proteins
        • Antisense, RNAi, & Molecular Therapy
        • Others
      • By Disease Category
        • Oncology
          • By Product
            • MABs
            • Vaccines
            • Recombinant Proteins
            • Antisense, RNAi, & Molecular Therapy
            • Others
          • Infectious Diseases
            • By Product
              • Vaccines
              • MABs
              • Antisense, RNAi, & Molecular Therapy
              • Recombinant Proteins
              • Others
            • Immunological Disorders
            • Cardiovascular Disorders
            • Hematological Disorders
            • Others
          • By Biologics Manufacturing
            • Outsourced
            • In-house
  1. Global Biologics Market Overview, By Region
    • North America Biologics Market Revenue (USD Billion), by Countries, (2022-2030)
      • US
        • By Source
        • By Product
        • By Disease Category
        • By Biologics Manufacturing
      • Canada
      • Mexico
    • Europe Biologics Market Revenue (USD Billion), by Countries, (2022-2030)
      • France
      • UK
      • Spain
      • Russia
      • Italy
      • BENELUX
    • Asia Pacific Biologics Market Revenue (USD Billion), by Countries, (2022-2030)
      • China
      • Japan
      • Australia
      • South Korea
      • India
      • ASEAN
  1. Latin America Biologics Market Revenue (USD Billion), by Countries, (2022-2030)
    • Brazil
    • Argentina
    • Chile
  2. Middle East and Africa Biologics Market Revenue (USD Billion), by Countries, (2022-2030)
    • GCC
    • Turkey
    • South Africa
  3. Global Biologics Market Revenue: Competitive Analysis, 2021
    • Key strategies by players
    • Revenue (USD Billion and %), By manufacturers, 2021
    • Player Positioning by Market Players, 2021
  4. Competitive Analysis
    • Samsung BioLogics
      • Business Overview
      • Business Financials (USD billion)
      • Product Category, Source, and Specification
      • Main Business/Business Overview
      • Geographical Analysis
      • Recent Development
      • Swot Analysis
    • Amgen
    • Novo Nordisk A/S
    • AbbVie Inc.
    • Sanofi
    • Johnson & Johnson Services, Inc
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GSK group of companies
    • Celltrion
    • Precision Biologics, Inc.
    • Merck KGaA
    • Eli Lilly and Company
    • Novartis AG
    • Bayer AG
    • Hoffmann-La Roche Ltd
    • AstraZeneca
  5. Market Research Findings & Conclusion

Disclaimer 

Research Methodology

The Market Research Community offers numerous solutions and its full addition in the research methods to be skilled at each step. We use wide-ranging resources to produce the best outcome for our customers. The achievement of a research development is completely reliant on the research methods implemented by the company. We always faithful to our clients to find opportunities by examining the global market and offering economic insights.

Market Research Community are proud of our widespread coverage that encompasses the understanding of numerous major industry domains. Company offers consistency in our research report, we also offers on the part of the analysis of forecast across a range of coverage geographies and coverage. The research teams carry out primary and secondary research to carry out and design the data collection methods.

Biologics Market Share, Size by Source (Microbial) Product (Monoclonal Antibodies) by Disease Category (Oncology), by Biologics Manufacturing (Outsourced) and Region (Asia Pacific, Europe, North America, Middle East, and Africa, Latin America), and forecast period-2022 – 2030 (Updated Version Available)
Back to top button